Gerresheimer (GXI) Panoramica del titolo
Gerresheimer AG, insieme alle sue consociate, produce e vende imballaggi per medicinali, dispositivi per la somministrazione di farmaci e soluzioni in Germania e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 1/6 |
| Salute finanziaria | 0/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
GXI Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeConcorrenti di Gerresheimer AG
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €24.54 |
| Massimo di 52 settimane | €66.50 |
| Minimo di 52 settimane | €14.83 |
| Beta | 0.33 |
| Variazione di 1 mese | 32.22% |
| Variazione a 3 mesi | -3.46% |
| Variazione di 1 anno | -59.47% |
| Variazione a 3 anni | -74.97% |
| Variazione a 5 anni | -72.94% |
| Variazione dall'IPO | -36.01% |
Notizie e aggiornamenti recenti
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.
GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.
GXI: FY25 Warning And Deferred Results Will Pressure Shares Further
Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.Recent updates
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.GXI: FY25 Warning And Deferred Results Will Pressure Shares Further
Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.GXI: Reset After FY25 Warning Will Set Up Future Earnings Reappraisal
Analysts have reduced their price target for Gerresheimer to about €46 from about €52, citing a higher discount rate and lower assumed future P/E, along with updated revenue growth and profit margin assumptions, as well as recent cautious Street research following the FY25 warning. Analyst Commentary The latest Street research has turned more cautious after the FY25 warning, with at least one major broker shifting to a Sell stance and cutting its price target to €12.90 from €29.GXI: Deferred Results And Softer Outlook Will Keep Shares Fairly Priced
Analysts have adjusted their price target on Gerresheimer to €18.90 from €22.00 as they now apply a slightly higher discount rate, a lower assumed revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Gerresheimer issued earnings guidance for 2026, targeting revenues of around €2.3b to €2.4b (company guidance).Investors Don't See Light At End Of Gerresheimer AG's (ETR:GXI) Tunnel
Feb 10
GXI: Index Inclusion And Higher P/E Assumptions Will Support Long-Term Confidence
Analysts have modestly lifted their price target for Gerresheimer, citing small adjustments to fair value and discount rate assumptions, as well as revised expectations for revenue growth, profit margins and future P/E. What's in the News Gerresheimer AG has been added to the Germany SDAX (Total Return) Index, highlighting its inclusion in this segment of the German equity market (Key Developments).GXI: Reset Expectations Will Set Up Future Reappraisal Of Earnings Quality
Analysts have trimmed their average price target on Gerresheimer to €30 from €55. The change reflects updated expectations for revenue growth, profit margins and future P/E multiples following recent research reviews.GXI: Profit Warnings Reset Expectations While Drug Delivery Platform Will Drive Reassessment
Gerresheimer's updated fair value estimate has been cut from about €97.07 to around €51.97 as analysts reset price targets sharply lower, citing reduced earnings visibility, a higher discount rate and increased uncertainty following recent profit warnings and rating downgrades. Analyst Commentary Recent Street research has turned more cautious on Gerresheimer, with several firms lowering price targets and adjusting ratings following profit warnings and reduced visibility on the investment case.GXI: Profit Warnings And Weak Outlook Will Pressure Shares Further
Gerresheimer's analyst price target has been cut sharply from about EUR 47.50 to EUR 22.00, as analysts factor in lower growth, thinner margins, a higher discount rate, and reduced valuation multiples following multiple target downgrades and rising uncertainty around the investment case. Analyst Commentary Bearish analysts have made a series of aggressive downward revisions to Gerresheimer's valuation, cutting price targets from prior levels as high as EUR 99.30 to a range between EUR 23 and EUR 46.GXI: Long-Term Sector Demand Will Support Confidence Despite Recent Profit Warnings
Analysts have cut their price target on Gerresheimer sharply, from roughly EUR 35 to about EUR 34. This reflects reduced fair value estimates as they factor in lower visibility on the investment case, successive target downgrades across the Street, and ongoing uncertainty following multiple profit warnings.These 4 Measures Indicate That Gerresheimer (ETR:GXI) Is Using Debt In A Risky Way
Nov 30GXI: Long-Term Sector Demand Will Support Confidence After Recent Leadership Change
Gerresheimer's analyst price targets have been significantly reduced recently, with analysts citing ongoing uncertainties and diminished near-term visibility as key factors for the downward revision. Previous targets exceeded €50, but new values are now in the €23 to €46 range.GXI: Confidence Will Remain Despite Current Uncertainties And Leadership Transition
Gerresheimer's analyst fair value target has been revised downward from €37.84 to €34.62. This change reflects recent broad cuts in price targets by analysts, who cite low visibility and ongoing uncertainties around the company's outlook.Lacklustre Performance Is Driving Gerresheimer AG's (ETR:GXI) 27% Price Drop
Nov 02Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead
Gerresheimer's analyst price target has been significantly reduced from €56.36 to €37.84. Analysts cite heightened uncertainties, reduced growth expectations, and a lack of near-term catalysts as reasons for this more cautious outlook.New Production Lines In Lohr And Skopje Will Improve Efficiency
Analysts have lowered their price target for Gerresheimer from €63.72 to €56.36. They cite more cautious expectations for revenue growth and profitability going forward.New Production Lines In Lohr And Skopje Will Improve Efficiency
The downward revision in Gerresheimer’s price target reflects recent declines in both net profit margin and consensus revenue growth forecasts, resulting in a reduced fair value estimate from €66.84 to €63.72. What's in the News Wolf Lehmann appointed as incoming CFO, succeeding Dr. Bernd Metzner; Lehmann brings nearly 30 years of international finance and management experience.Why We're Not Concerned About Gerresheimer AG's (ETR:GXI) Share Price
Sep 18Here's Why Gerresheimer (ETR:GXI) Is Weighed Down By Its Debt Load
Jul 31Positive Sentiment Still Eludes Gerresheimer AG (ETR:GXI) Following 28% Share Price Slump
Jun 18Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package
May 30Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
May 29Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)?
May 14Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Apr 24Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders
Apr 19It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks
Apr 11Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
Apr 10Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
Mar 05Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge
Feb 25
Expansion Into High-Margin Biologics And Devices Indicates Strong Future Prospects
Strategic expansion into high-margin segments like drug delivery systems and ready-to-use vials could enhance revenue and EBITDA margins significantly.Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Jan 12Is It Time To Consider Buying Gerresheimer AG (ETR:GXI)?
Dec 26Gerresheimer AG Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next
Oct 03Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Sep 29Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
Aug 31Shareholders Will Most Likely Find Gerresheimer AG's (ETR:GXI) CEO Compensation Acceptable
May 30Rendimenti per gli azionisti
| GXI | DE Life Sciences | DE Mercato | |
|---|---|---|---|
| 7D | 7.3% | 0.3% | 0.06% |
| 1Y | -59.5% | -19.5% | 1.0% |
Ritorno vs Industria: GXI ha avuto una performance inferiore rispetto al German Life Sciences che ha registrato un rendimento -19.5 % nell'ultimo anno.
Rendimento vs Mercato: GXI ha avuto una performance inferiore al mercato German che ha registrato un rendimento 1 % nell'ultimo anno.
Volatilità dei prezzi
| GXI volatility | |
|---|---|
| GXI Average Weekly Movement | 16.2% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di GXI è stato volatile rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale di GXI è aumentata da 10% a 16% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1864 | 13,535 | Uwe Röehrhoff | www.gerresheimer.com |
Gerresheimer AG, insieme alle sue consociate, produce e vende imballaggi per medicinali, dispositivi per la somministrazione di farmaci e soluzioni in Germania e a livello internazionale. Opera attraverso tre divisioni: Plastics & Devices, Primary Packaging Glass e Advanced Technologies. L'azienda offre siringhe preriempibili, soluzioni di confezionamento in plastica e vetro, fiale, cartucce e ampolle in vetro, flaconi e contenitori, bottiglie e vasetti in vetro, nonché tappi, chiusure, applicatori e accessori; sviluppo, industrializzazione e produzione a contratto di programmi di somministrazione di farmaci; gestione di progetti e qualità; sistemi di somministrazione di farmaci, tra cui inalatori, iniettori/autoiniettori, iniettori a penna, sistemi di infusione e valutazione dell'inalazione, autoiniettori e altri servizi.
Gerresheimer AG Riepilogo dei fondamenti
| GXI statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €847.61m |
| Utili (TTM) | €23.35m |
| Ricavi(TTM) | €2.25b |
GXI è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| GXI Conto economico (TTM) | |
|---|---|
| Ricavi | €2.25b |
| Costo del fatturato | €1.65b |
| Profitto lordo | €605.15m |
| Altre spese | €581.80m |
| Utili | €23.35m |
Ultimi utili riportati
Aug 31, 2025
Prossima data di guadagno
Jul 14, 2026
| Utile per azione (EPS) | 0.68 |
| Margine lordo | 26.89% |
| Margine di profitto netto | 1.04% |
| Rapporto debito/patrimonio netto | 155.5% |
Come si è comportato GXI nel lungo periodo?
Vedi performance storica e confrontoDividendi
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/03 22:37 |
| Prezzo dell'azione a fine giornata | 2026/04/30 00:00 |
| Utili | 2025/08/31 |
| Utili annuali | 2024/11/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Gerresheimer AG è coperta da 35 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jonathon Unwin | Barclays |
| Pallav Mittal | Barclays |
| Gaurav Jain | Barclays |